Filing Flows › Travere Therapeutics (TVTX) › Q3 2025
Travere Therapeutics (TVTX) Q3 2025 earnings results (third quarter 2025)
10-Q filed Oct 30, 2025
Travere Therapeutics (TVTX) reported revenue of $165M for the third quarter 2025 (Q3 2025), +162% from a year earlier and +44% from the quarter before. Operating margin was 15.1%, net earnings $25.7M (15.6% of revenue).
Travere Therapeutics, Q3 2025: revenue $165M (+162% year over year), operating margin 15.1%, net earnings $25.7M, operating cash flow $14.3M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $165M | +44% | +162% |
| Operating profit | $24.9M | — | — |
| Net earnings | $25.7M | — | — |
| Operating cash flow | $14.3M | +187% | — |
| Free cash flow | $14.2M | — | — |
What changed
Revenue was $164.9M in Q3 2025, up 162% year over year and up 44% from the previous quarter. FILSPARI was the largest line at 55% of revenue. FILSPARI added $55.3M year over year (up 155%), 54% of the total change. Tiopronin products declined 12%.
Operating profit was $24.9M, a 15.1% margin (up 104.4 points year over year). Total costs grew 18% against revenue growth of 162%. The fastest-growing cost line was SG&A (+32%). Net earnings were $25.7M. The effective tax rate was 0.0%.
Operating cash flow was $14.3M, 56% of net earnings. Non-cash charges added back $15.8M of depreciation and amortization and $11.3M of share-based compensation. Working capital and other items used $38.4M. Capital expenditures of $140K left free cash flow of $14.2M.
Questions
What was Travere Therapeutics' revenue in the third quarter 2025?
Travere Therapeutics (TVTX) reported revenue of $165M for the third quarter 2025 (Q3 2025), +162% from a year earlier and +44% from the quarter before.
Was Travere Therapeutics profitable in the third quarter 2025?
Operating profit was $24.9M (15.1% of revenue) and net earnings $25.7M.